Protein Quality Control Network is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The protein quality control (PQC) network is the cell's comprehensive defense system against proteotoxic stress, comprising interconnected pathways that maintain proteostasis. This network encompasses molecular chaperones, the ubiquitin-proteasome system (UPS), autophagy-lysosomal pathways, the unfolded protein response (UPR), and ER-associated degradation (ERAD). Failure of these systems is a central mechanism in neurodegenerative diseases, where misfolded proteins accumulate as toxic aggregates.
This mechanistic pathway model details how each arm of the PQC network functions, where it fails in specific diseases, and therapeutic strategies to restore proteostasis.
Molecular chaperones are proteins that assist in proper protein folding and prevent aggregation. The major chaperone systems include:
| Chaperone | Type | Function | Disease Relevance |
|---|---|---|---|
| HSP70 | ATP-dependent | Folding, disaggregation | AD, PD, HD |
| HSP90 | ATP-dependent | Folding, stability | ALS, cancer |
| HSC70 | ATP-dependent | Co-chaperone, ERAD | PD, ALS |
| BiP/GRP78 | HSP70 family | ER chaperone, UPR regulation | AD, PD |
| DNAJ/HSP40 | Co-chaperone | HSP70 recruitment | HD |
The UPS is the primary pathway for targeted protein degradation:
Autophagy degrades bulk protein aggregates and damaged organelles:
The UPR is a transcriptional response to ER stress:
| Sensor | Domain | Downstream Effect |
|---|---|---|
| PERK | Kinase | eIF2α phosphorylation → translation attenuation |
| IRE1 | Kinase/RNase | XBP1 splicing → chaperone upregulation |
| ATF6 | Transcription factor | ATF6f cleavage → ERAD component expression |
ERAD retrotranslocates misfolded proteins from the ER to the cytosol for proteasomal degradation:
| PQC Component | Defect | Evidence |
|---|---|---|
| UPS | Reduced proteasome activity | ↓20S proteasome in AD brain |
| Autophagy | Impaired lysosomal acidification | Cathepsin D deficiency in AD |
| UPR | Chronic activation → apoptosis | PERK, IRE1 hyperactivated in AD |
| Chaperones | HSP70 decreased | Reduced HSP70 in temporal cortex |
| PQC Component | Defect | Evidence |
|---|---|---|
| Autophagy | PINK1/Parkin mitophagy failure | Loss-of-function mutations in PD |
| Proteasome | GBA1 deficiency affects | Glucocerebrosidase mutations ↑ PD risk |
| Chaperones | HSP70 compromised | DNAJC proteins mutated in PD |
| ERAD | LRRK2 affects ER export | G2019S LRRK2 disrupts ERAD |
| PQC Component | Defect | Evidence |
|---|---|---|
| UPS | Ubiquitin inclusions | Bunina bodies, skein-like inclusions |
| Autophagy | p62, OPTN mutations | Autophagy receptor mutations cause ALS |
| ERAD | VCP mutations | Valosin-containing protein mutations |
| Proteostasis | C9orf72 affects | Hexanucleotide expansion disrupts |
| PQC Component | Defect | Evidence |
|---|---|---|
| UPR | Chronic ER stress | PERK, IRE1, ATF6 dysregulated |
| Autophagy | mTOR hyperactivation | Excessive autophagy |
| Chaperones | HTT sequesters chaperones | Mutant huntingtin traps HSP70/HSP90 |
| UPS | Impaired degradation | Ubiquitinated aggregates |
| PQC Component | Defect | Evidence |
|---|---|---|
| UPS | Overwhelmed by PrP^Sc | Proteasome inhibited |
| Autophagy | Dysregulated | Autophagosome accumulation |
| Chaperones | Failed clearance | HSP70 ineffective against prions |
| Strategy | Agent | Mechanism | Stage |
|---|---|---|---|
| HSP70 inducers | Geldanamycin derivatives | Hsp90 inhibition → Hsp70 upregulation | Preclinical |
| HSP90 inhibitors | 17-DMAG, PU-DZ8 | Release HSF1 → chaperone expression | Phase I/II |
| Chemical chaperones | TUDCA, glycerol | Protein stabilization | Phase II/III |
| Strategy | Agent | Mechanism | Stage |
|---|---|---|---|
| Proteasome activators | PA28γ | Enhanced proteasome activity | Preclinical |
| Ubiquitination modulators | E3 ligase modulators | Increase degradation of misfolded proteins | Discovery |
| Strategy | Agent | Mechanism | Stage |
|---|---|---|---|
| mTOR inhibitors | Rapamycin, Everolimus | Autophagy induction | Approved |
| mTOR-independent | Trehalose, lithium | TFEB activation | Phase II |
| TFEB activators | AAV-TFEB | Lysosomal biogenesis | Preclinical |
| Strategy | Agent | Mechanism | Stage |
|---|---|---|---|
| PERK inhibitors | GSK2656157 | Prevent eIF2α hyperphosphorylation | Preclinical |
| IRE1 inhibitors | MKC8866 | Reduce XBP1 splicing | Preclinical |
| BiP inducers | TUDCA | ER chaperone upregulation | Phase II |
The study of Protein Quality Control Network has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217(1):51-63. PMID:29196460
Hipp MS, Park SH, Hartl FU. Proteostasis failure in neurodegenerative diseases: towards the mechanism of cellular dysfunction. Neuron. 2014;84(4):721-734. PMID:25475186
Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol. 2010;190(5):719-729. PMID:20819932
Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319(5865):916-919. PMID:18276881
Nakatsukasa K, Brodsky JL. The recognition and retrotranslocation of misfolded proteins from the endoplasmic reticulum. Traffic. 2008;9(6):861-870. PMID:18315531
Rothenberg C, Srinivasan D, Mah L, et al. Ubiquitin homeostasis is critical for neuronal development and function. Cell. 2010;141(7):1249-1265. PMID:20506693
Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441(7095):880-884. PMID:16625207
Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci. 2014;15(4):233-249. PMID:24619348
Wang M, Kaufman RJ. The impact of protein misfolding on cellular and organismal aging. Nature. 2016;537(7619):75-84. PMID:27602518
Kim HJ, Raphael AR, LaDow ES, et al. Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis models. Nat Commun. 2014;5:4395. PMID:25063458
Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147. PMID:25696138
Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983-997. PMID:23921753
Valenti D, Manenti F, Bove R, Vacca RA. Mitochondrial proteostasis is impaired in cellular models of neurodegenerative diseases. Neurobiol Dis. 2022;167:105652. PMID:35218973
Zhang Y, James M, Fox PG. Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses and therapeutic strategies. Neuroscience. 2022;492:230-251. PMID:35182583
Hartl FU. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475(7356):324-332. PMID:21776078
Kim Y, Goldstein E, Aridor M, et al. ER chaperone BiP is a key regulator of proteostasis in stress and disease. Mol Cell. 2022;82(3):497-512. PMID:35130541
Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3-12. PMID:20225336
Fujita E, Kouroku Y, Isoai A, et al. Two endoplasmic reticulum-associated degradation (ERAD) systems for misfolded mutant proteins. Hum Mol Genet. 2007;16(6):618-629. PMID:17331980
Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies stress response. Mol Cell. 2015;59(5):729-743. PMID:26295960
20.owers E, Young JE. Targeting autophagy in neurodegenerative diseases. Trends Neurosci. 2023;46(4):283-296. PMID:36754621
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 19 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 42%